At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United Kingdom based CTO’ operating in the Biotechnology space. If you think a CTO’ is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Charles Lewinton
Chief Technology Officer of Buddi
Charles has been working in the Electronic Monitoring industry for the last 12 years with a focus on bringing new technology to the field in both software and hardware products. He has a background in large scale software development with a focus on reducing operational costs using innovate software combined with smart hardware. He has led on the roll out of various international electronic monitoring and other government projects, focusing on the technical project management areas and challenges. Charles has been with buddi now for 2 years and has been able to help shape both software and hardware solutions for buddi’s market leading products.
Follow Charles Lewinton:
About Buddi: Buddi is an innovative, high-growth and british technology company that develops location and health monitoring technologies.
Charles Blundell
Founder & CTO of C4X Discovery
Charles invented C4XD’s core Conformetrix technology, founded the Company and led the spin-out from The University of Manchester in 2008 with Dr. Andrew Almond. Charles has been awarded multiple grants from top UK research councils during his career and has published over 20 research articles in leading scientific journals. He studied for his undergraduate masters degree and DPhil in Biochemistry at the University of Oxford (Keble College), graduating within the top 5 of his peer group.
Follow Charles Blundell:
About C4X Discovery: C4X Discovery brings a new dimension to drug discovery. Using its unique NMR-based technique to determine 3D molecular.
James Thomas
Chief Technology Officer of Wellcome Trust
James joined Wellcome in April 2016. He is responsible for leadership of our technology and digital services. Before Wellcome, James had an extensive career in the private and public sectors, delivering transformational change through technology and data. His career began in the oil and water industries, with BP and Veolia. He moved to global technology provider Oracle to develop and lead technology consulting services for clients, including banking, defence and manufacturing. He then moved into healthcare, with technology leadership roles in the NHS. This included eight years as a Director of UCL Hospitals, establishing UCL Partners, London NHS Procurement Partnership and the UCH Macmillan Cancer Centre. Following this, James became an Associate Partner at Atos Consulting, including working with Genomics England to review its Informatics and bioinformatics capabilities.
Follow James Thomas:
About Wellcome Trust: Wellcome Trust is a medical research charity that funds research that aims to protect and improving human and animal health.
Pablo Prieto Barja
CTO and Co-Founder of Lifebit
Follow Pablo Prieto Barja:
About Lifebit: Lifebit CloudOS is the intelligent genomics platform that is the industry standard for unified, secure research over distributed big data.
Ben Mills-Lamptey
CTO of bio-bean
Ben Mills-Lamptey is the Chief Technology Officer at Bio Bean.
Follow Ben Mills-Lamptey:
About bio-bean: bio-bean is a U.K.-based green company that offers its users with processes of recycling and waste management solutions.
Craig Johnston
CTO & Co-Founder of ENOUGH
Follow Craig Johnston:
About ENOUGH, Swedish Biomimetics 3000: ENOUGH is a foodtech startup producing protein through fermenting fungi using renewable feedstocks.
Eric Greveson
CTO of Brainomix
Eric is the CTO of Brainomix. He received his 1st class M.Eng.in Engineering from Cambridge University, and has worked on a wide variety of computer vision projects. These include video processing and 3D graphics algorithms, real-time data capture software, parallel grid computing systems, and data visualization. He has extensive experience in software engineering, design, and programming with languages such as C++ and Python. At Brainomix, Eric works with the clinical and business teams to deliver the company’s state-of-the-art medical imaging software.
Follow Eric Greveson:
About Brainomix: Brainomix specializes in the creation of AI-powered imaging biomarkers that enable precision medicine for better treatment decisions
Matthew Simmonds
Chief Technology Officer of Entocycle
Forbes 30 under 30 entrepreneur, built and sold a tech company to the NHS, 1st class Oxford engineering graduate, guitar shredder.
Follow Matthew Simmonds:
About Entocycle: Entocycle’s automated insect farm produces environmentally friendly insect protein to feed farmed animals.
Radouane Oudrhiri
Chief Technology Officer of Eagle Genomics
Radouane has an extensive experience in leading world-class software and data-intensive system developments in different industries from Telecom to Healthcare, Nuclear, Automotive, Financials. Radouane is Lean/Six Sigma Master Black Belt with speciality in high-tech, IT and Software engineering and he is recognised as the leader and early adaptor of Lean/Six Sigma and DFSS to IT and Software. He is a fellow of the Royal Statistical Society (RSS) and member of the ISO Technical Committee (TC69: Applications of Statistical methods) where he is co-author of the Lean & Six Sigma Standard (ISO 18404) as well as the new standard under development (Design for Six Sigma). He is also part of the newly formed international Group on Big Data (nominated by BSI as the UK representative/expert). Radouane has also been Chair of the working group on Measurement Systems for Automated Processes/Systems within the ISPE (International Society for Pharmaceutical Engineering).
Follow Radouane Oudrhiri:
About Eagle Genomics: Eagle Genomics is a enterprise software solutions company to enable the management, orchestration and exploitation of life sciences data.
Caroline Hargrove
CTO of Zedsen
Caroline currently works as Chief Technology Officer at Zedsen. She was the acting CTO of McLaren Applied Technologies (MAT). She has experience in developing innovative technology solutions in sectors including Motorsports, Transport, Health, Elite sports, Manufacturing, and Energy. Caroline joined the McLaren F1 team in 1997 where she worked in vehicle dynamics and spearheaded the development of the McLaren F1 simulator. In 2008, she joined MAT as the third employee and has played a pivotal role in developing MAT from a start-up to a successful forward-looking technology company. She is also a Visiting Professor in Surgical Simulations at Oxford and a Fellow of the Royal Academy of Engineering.
Follow Caroline Hargrove:
About Zedsen: Zedsen provides biosensors that create a 3-Dimensional electrical field and gathers biological signals within a human body.
Philip Kunovski
CTO & Head of Research of KYMIRA Sport
Follow Philip Kunovski:
About KYMIRA Sport: KYMIRA Sport is developing a range of performance and recovery enhancing sportswear.
Lindsay Edwards
Chief Technology Officer and President of Platform of Relation Therapeutics
Lindsay Edwards is the Chief Technology Officer and President of Platform of Relation Therapeutics.
Follow Lindsay Edwards:
About GlaxoSmithKline, Relation Therapeutics: Relation Therapeutics engages in humanizing drug discovery and development.
Ferdinando Randisi
Co Founder & CTO of FabricNano
Follow Ferdinando Randisi:
About FabricNano: FabricNano is a cell-free biomanufacturing company that develops a DNA-based flow reactor to unlock the future of biochemistry.
Martin Challand
CTO and Co-Founder of Zentraxa
Leads technology and product research and development. Martin has a master’s degree in Chemistry and a PhD in Chemical Biology, both from the University of Southampton and over 9 years R&D experience across academia and industry working at the interface of chemistry and biology. In 2015 he took up a post-doctoral research position in Synthetic Biology at the University of Bristol to lead the development of the Zentide technology and subsequently co-founded Zentraxa in 2017.
Follow Martin Challand:
About Zentraxa: Zentraxa has specialise in the design, production and testing of complex novel peptides.
Derek Stemple
CTO and Co-Founder of Camena Bioscience
Derek Stemple is the CTO and co-founder of Camena Bioscience. He previously held senior positions at the Wellcome Trust Sanger Institute and was a lab head at the National Institute for Medical Research. Derek holds a Ph.D. from the California Institute of Technology.
Follow Derek Stemple:
About Camena Bioscience: Camena Bioscience is a synthetic biology company that develops tools to engineer new synthetic biology applications.
Jane Osbourn
Co-Founder, Chief Scientific Officer & Chief Technology Officer of Alchemab Therapeutics
Jane Osbourn is the chairman at Mogrify.
Follow Jane Osbourn:
About Alchemab Therapeutics: Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases.
William Jones
CTO & Co-Founder of Sano Genetics
Follow William Jones:
About Sano Genetics: Sano Genetics is a personalised medicine research platform with data privacy and transparency at its core.
Jaya Krishnan
Co-founder & CTO of Genome Biologics
Prof. Jaya Krishnan has more than 20 years experience in preclinical models and cardiovascular disease research. He completed his PhD at Imperial College London and led research at the ETH-Zurich, Medical Research Council UK and Imperial College London. He currently leads an RNA Therapeutics group in Germany.
Follow Jaya Krishnan:
About Genome Biologics: Genome Biologics identifies novel tissue-specific RNAi therapies targeting the transcriptome of cardiovascular and cardiometabolic disease
Bruce Vernon
CTO of Calcivis
Bruce, with a Master’s degree in Immunology, has over 30 years’ experience within GLP and GMP licensed manufacturing facilities. As Operations Site Manager, he was previously responsible for all activities at Intercell’s cGMP vaccine manufacturing plant. Prior to this Bruce held a number of senior management positions within the Biopharmaceutical Industry including Global Head of Quality and Qualified Person for Intercell (where he established and implemented quality and compliance systems to meet FDA, EMA and other international regulatory requirements) and senior management posts at Excell Biotech Ltd., and Serologicals (now part of Millipore) specialist Biologics manufacturers of cGMP medicinal products and medical devices. Bruce is eligible to act as a Qualified Person under the permanent provisions of Directive 2001/82/EC and 2001/83/EC for both commercially licensed and investigational medicinal products.
Follow Bruce Vernon:
About Calcivis, ProFactor Pharma, VYVO BioSolutions: Calcivis is a biotech company that focuses on unmet needs in dentistry.
Robert Simion
CTO & Co-founder of EnzBond
Robert holds a PhD in Organic Chemistry from Oxford University. He has more than 8 years of research experience with main focus on computational and organic chemistry. Robert has published several peer-reviewed papers and has consulted for companies within biotechnology.
Follow Robert Simion:
About EnzBond: In-silico development of enzymes for pharma
David Bunka
Director & CTO of Aptamer Group
Dave holds a Ph.D. in Molecular Biology from the University of Leeds and is a Geneticist by training. He spent 12 years developing high throughput automated aptamer selection methods at the University of Leeds. David has built up a solid international reputation in the field. Since 2003 David has isolated ~200 aptamers against a wide variety of targets including: small molecule antibiotics, food contaminants, disease associated proteins, several cancer associated cell-lines, viruses and patient tissue samples. Since joining the group officially in 2012 David had developed over 50 aptamers to various targets and has development several patentable process variations. David has authored several aptamer papers in peer reviewed journals, including 2 invited review articles and a book chapter in 2012 for the Royal Society of Chemistry entitled “therapeutic uses of nucleic acid aptamer conjugates”.
Follow David Bunka:
About Aptamer Group: Aptamer Group develop DNA and RNA nucleic acid aptamers for use in R&D, biomarker discovery, diagnostics or therapeutic developments.
Sam Bruggen
Co-founder & CTO of ThinAir
Sam Bruggen is a Co-Founder and Chief Technology Officer at ThinAir Water.
Follow Sam Bruggen:
About ThinAir: ThinAir – bringing water to water scarce communities across the globe.
Andrew Lovatt
Chief Technology Officer of Blacktrace Ltd
Andrew Lovatt currently serves Blacktrace Holdings as a chief technology officer. Prior to joining Blacktrace Holdings, Andrew spent three years with the Dolomite Microfluidics as chief technology officer.
Follow Andrew Lovatt:
About Blacktrace Ltd: Blacktrace Ltd is a technology company specializing in biology, nanomaterial sciences, chemistry, and microfluidics.
Gordon McInroy
Founder and CTO of Nuclera
Follow Gordon McInroy:
About Nuclera: Nuclera makes biology accessible through desktop enzymatic protein and gene synthesis.
Ben Holland
Co-founder and CTO of Antiverse
Ben Holland is the Co-founder and CTO at Antiverse.
Follow Ben Holland:
About Antiverse: Engineering the future of drug discovery
Gustavo Cerda
CTO of Swift Molecular Diagnostics
Gustavo completed his PhD at the University of Cambridge in the field of molecular biology. He then went on to do a successful Post-doc also at the University of Cambridge. Using his knowledge of molecular biology, he discovered a revolutionary method of detecting DNA. He now works full time for Swift Molecular Diagnostics.
Follow Gustavo Cerda:
About Swift Molecular Diagnostics: Swift Molecular Diagnostics is developing a rapid, easy-to-use, cost effective genetic “yes or no” test.
Justin Buckland
CTO of LEX Diagnostics
Justin Buckland is the Chief Technology Officer of LEX Diagnostics.
Follow Justin Buckland:
About LEX Diagnostics: LEX Diagnostics is a medical device company that specializes in molecular diagnostics for primary care.
David Moffat
Chief Technology Officer of Macrophage Pharma
Follow David Moffat:
About Macrophage Pharma: Macrophage Pharma is a immune-oncology company
David Moffat
Chief Technology Officer of Macrophage Pharma
Follow David Moffat:
About Macrophage Pharma: Macrophage Pharma is a immune-oncology company
